| 臺大學術典藏 |
2021-06-15T03:12:02Z |
Elderly Adults with Late-Onset Ulcerative Colitis Tend to Have Atypical, Milder Initial Clinical Presentations but Higher Surgical Rates and Mortality: A Taiwan Society of Inflammatory Bowel Disease Study
|
Lin W.-C.; Tung C.-C.; Lin H.-H.; Lin C.-C.; Chang C.-W.; Yen H.-H.; Chuang C.-H.; Hsu W.-H.; Tsai W.-S.; Wang H.-Y.; Lin J.-K.; SHU-CHEN WEI; Wong J.-M. |
| 臺大學術典藏 |
2021-06-15T03:12:01Z |
Management of ulcerative colitis in Taiwan: Consensus guideline of the Taiwan Society of inflammatory bowel disease
|
SHU-CHEN WEI; Chang T.-A.; Chao T.-H.; Chen J.-S.; Chou J.-W.; Chou Y.-H.; Chuang C.-H.; Hsu W.-H.; Huang T.-Y.; Hsu T.-C.; Lin C.-C.; Lin H.-H.; Lin J.-K.; Lin W.-C.; Ni Y.-H.; Shieh M.-J.; Shih I.-L.; Shun C.-T.; Tsang Y.-M.; Wang C.-Y.; Wang H.-Y.; Weng M.-T.; Wu D.-C.; Wu W.-C.; Yen H.-H.; Wong J.-M. |
| 臺大學術典藏 |
2021-06-15T03:12:01Z |
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
|
Lin W.-C.; Chou J.-W.; Yen H.-H.; Hsu W.-H.; Lin H.-H.; Lin J.-K.; Chuang C.-H.; Huang T.-Y.; Wang H.-Y.; SHU-CHEN WEI; Wong J.-M. |
| 臺大學術典藏 |
2021-05-26T09:08:27Z |
PIG-A gene mutations in four Taiwanese patients with paroxysmal nocturnal haemoglobinuria following aplastic anaemia
|
Lin L.-I.; Liu C.-H.; YAO-CHANG CHEN; Shen M.-C.; Wang C.-H.; Huang Y.-L.; Lin J.-K. |
| 臺大學術典藏 |
2021-05-26T03:36:18Z |
Penicillinase-type of β-lactamase responsible for the ampicillin resistance in Escherichia coli NTUH 9501-1
|
Lin J.-K.; Huang T.-S.; KWEN-TAY LUH |
| 臺大學術典藏 |
2021-05-06T01:53:14Z |
Molecular pathogenesis of paroxysmal nocturnal hemoglobinuria
|
Lin L.-I.; YEE-CHUN CHEN; Lin J.-K. |
| 臺大學術典藏 |
2021-03-18T02:02:34Z |
Management of Crohn's disease in Taiwan: Consensus guideline of the Taiwan society of inflammatory bowel disease
|
Wei S.-C.;Chang T.-A.;Chao T.-H.;Chen J.-S.;Chou J.-W.;Chou Y.-H.;Chuang C.-H.;Hsu W.-H.;Huang T.-Y.;Hsu T.-C.;Lin C.-C.;Lin H.-H.;Lin J.-K.;Lin W.-C.;Ni Y.-H.;Shieh M.-J.;Shih I.-L.;Chia-Tung Shun;Tsang Y.-M.;Wang C.-Y.;Wang H.-Y.;Weng M.-T.;Wu D.-C.;Wu W.-C.;Yen H.-H.;Wong J.-M.; Wei S.-C.; Chang T.-A.; Chao T.-H.; Chen J.-S.; Chou J.-W.; Chou Y.-H.; Chuang C.-H.; Hsu W.-H.; Huang T.-Y.; Hsu T.-C.; Lin C.-C.; Lin H.-H.; Lin J.-K.; Lin W.-C.; Ni Y.-H.; Shieh M.-J.; Shih I.-L.; CHIA-TUNG SHUN; Tsang Y.-M.; Wang C.-Y.; Wang H.-Y.; Weng M.-T.; Wu D.-C.; Wu W.-C.; Yen H.-H.; Wong J.-M. |
| 臺大學術典藏 |
2021-03-18T02:02:33Z |
Management of ulcerative colitis in Taiwan: Consensus guideline of the Taiwan Society of inflammatory bowel disease
|
Wei S.-C.;Chang T.-A.;Chao T.-H.;Chen J.-S.;Chou J.-W.;Chou Y.-H.;Chuang C.-H.;Hsu W.-H.;Huang T.-Y.;Hsu T.-C.;Lin C.-C.;Lin H.-H.;Lin J.-K.;Lin W.-C.;Ni Y.-H.;Shieh M.-J.;Shih I.-L.;Chia-Tung Shun;Tsang Y.-M.;Wang C.-Y.;Wang H.-Y.;Weng M.-T.;Wu D.-C.;Wu W.-C.;Yen H.-H.;Wong J.-M.; Wei S.-C.; Chang T.-A.; Chao T.-H.; Chen J.-S.; Chou J.-W.; Chou Y.-H.; Chuang C.-H.; Hsu W.-H.; Huang T.-Y.; Hsu T.-C.; Lin C.-C.; Lin H.-H.; Lin J.-K.; Lin W.-C.; Ni Y.-H.; Shieh M.-J.; Shih I.-L.; CHIA-TUNG SHUN; Tsang Y.-M.; Wang C.-Y.; Wang H.-Y.; Weng M.-T.; Wu D.-C.; Wu W.-C.; Yen H.-H.; Wong J.-M. |
| 臺大學術典藏 |
2021-03-15T08:44:22Z |
p53 gene mutational spectra in hepatocellular carcinomas induced by 2?acetylaminofluorene and N?nitroso?2?acetylaminofluorene in rats
|
Ho Y.?S.; HUI-TENG CHENG; Wang Y.?J.; Lin J.?K. |
| 臺大學術典藏 |
2021-03-15T08:26:23Z |
p53 gene mutational spectra in hepatocellular carcinomas induced by 2?acetylaminofluorene and N?nitroso?2?acetylaminofluorene in rats
|
Ho Y.?S.; HUI-TENG CHENG; Wang Y.?J.; Lin J.?K. |
| 臺大學術典藏 |
2021-02-02T08:29:56Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; BOR-RU LIN; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:22:37Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Yeong-Shiau Pu;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y.; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; YEONG-SHIAU PU; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Li J.; Qin S.; Xu R.; Yau T.C.C.; Ma B.; Pan H.; Xu J.; Bai Y.; Chi Y.; Wang L.; KUN-HUEI YEH; Bi F.; Cheng Y.; Le A.T.; Lin J.-K.; Liu T.; Ma D.; Kappeler C.; Kalmus J.; Kim T.W. |
| 臺大學術典藏 |
2021-01-28T01:06:23Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
Cheng A.-L.;Cornelio G.;Shen L.;Price T.;Yang T.-S.;Chung I.J.;Dai G.-H.;Lin J.-K.;Sharma A.;Kun-Huei Yeh;Ma B.;Zaatar A.;Guan Z.;Masood N.;Srimuninnimit V.;Yau T.;Gibbs P.;Wang X.;Doval D.C.;Oh S.-T.;Shim B.Y.;Gorospe C.;Wang H.-M.;Sirachainan E.;Hill A.;Suh K.W.;Beier F.;Chatterjee S.;Lim R.; Cheng A.-L.; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; KUN-HUEI YEH; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 臺大學術典藏 |
2021-01-28T01:06:15Z |
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
|
Xu J.; Xu R.-H.; Qin S.; Pan H.; Bai Y.; Chi Y.; Wang L.; Bi F.; Cheng Y.; Liu T.; Ma D.; Shen L.; Ba Y.; Liang J.; Wang X.; Yau T.C.C.; Ma B.B.; KUN-HUEI YEH; Lin J.-K.; Kappeler C.; Shapiro J.; Kalmus J.; Li J. |
| 臺大學術典藏 |
2020-12-28T08:14:15Z |
Management of ulcerative colitis in Taiwan: Consensus guideline of the Taiwan Society of inflammatory bowel disease
|
Lin J.-K.; Lin W.-C.; Lin H.-H.; Lin C.-C.; Hsu T.-C.; Huang T.-Y.; Wei S.-C.; Chang T.-A.; Chao T.-H.; Chen J.-S.; Chou J.-W.; Chou Y.-H.; Chuang C.-H.; Hsu W.-H.; YEN-HSUAN NI; Shieh M.-J.; Shih I.-L.; Shun C.-T.; Tsang Y.-M.; Wang C.-Y.; Wang H.-Y.; Weng M.-T.; Wu D.-C.; Wu W.-C.; Yen H.-H.; Wong J.-M. |
| 臺大學術典藏 |
2020-12-28T08:14:15Z |
Management of Crohn's disease in Taiwan: Consensus guideline of the Taiwan society of inflammatory bowel disease
|
Lin J.-K.; Lin W.-C.; YEN-HSUAN NI; Shieh M.-J.; Shih I.-L.; Shun C.-T.; Tsang Y.-M.; Wang C.-Y.; Wang H.-Y.; Weng M.-T.; Wu D.-C.; Wu W.-C.; Yen H.-H.; Wong J.-M.; Wei S.-C.; Chang T.-A.; Chao T.-H.; Chen J.-S.; Chou J.-W.; Chou Y.-H.; Chuang C.-H.; Hsu W.-H.; Huang T.-Y.; Hsu T.-C.; Lin C.-C.; Lin H.-H. |
| 臺大學術典藏 |
2020-11-27T08:14:47Z |
Stability of curcumin in buffer solutions and characterization of its degradation products
|
Wang Y.-J.; Pan M.-H.; Cheng A.-L.; Lin L.-I.; Ho Y.-S.; CHANG-YAO HSIEH; Lin J.-K. |
| 臺大學術典藏 |
2020-11-27T08:14:44Z |
Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis
|
Chuang S.E.;Kuo M.L.;Hsu C.H.;Chen C.R.;Lin J.K.;Lai G.M.;Chang-Yao Hsieh;Cheng A.L.; Chuang S.E.; Kuo M.L.; Hsu C.H.; Chen C.R.; Lin J.K.; Lai G.M.; CHANG-YAO HSIEH; Cheng A.L. |
| 臺大學術典藏 |
2020-11-27T08:14:40Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Chang-Yao Hsieh; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; CHANG-YAO HSIEH |
| 臺大學術典藏 |
2020-11-27T08:14:39Z |
Pre-clinical and early-phase clinical studies of curcumin as chemopreventive agent for endemic cancers in Taiwan.
|
Hsu C.H.;Chuang S.E.;Hergenhahn M.;Kuo M.L.;Lin J.K.;Chang-Yao Hsieh;Cheng A.L.; Hsu C.H.; Chuang S.E.; Hergenhahn M.; Kuo M.L.; Lin J.K.; CHANG-YAO HSIEH; Cheng A.L. |
| 臺大學術典藏 |
2020-11-19T03:43:20Z |
Significance of nm23 mRNA expression in human hepatocellular carcinoma
|
Lin L.-I.; PO-HUANG LEE; Wu C.-M.; Lin J.-K. |
| 臺大學術典藏 |
2020-11-03T11:57:17Z |
Epigallocatechin gallate (EGCG) suppresses β-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3β activation
|
Lin C.-L.;Chen T.-F.;Ming-Jang Chiu;Way T.-D.;Lin J.-K.; Lin C.-L.; Chen T.-F.; MING-JANG CHIU; Way T.-D.; Lin J.-K. |
| 臺大學術典藏 |
2020-11-02T02:05:31Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Hsieh C.-Y.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Ho Y.-F.; Hsu M.-M.; Lin J.-K.; Hsu C.-H.; Chen A.-L. |
